Atopic dermatitis (AD) is a chronic inflammatory skin disease posing a significant burden on
health-care resources and patients' quality of life. It is a complex disease with a wide …

There is a growing desire to explain the worldwide rise in the prevalence of atopic dermatitis
(AD). Trend data on the burden of AD suggest that the picture in the develo** world may …

Background Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well
tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to …

Importance Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective
and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic …

BACKGROUND: In 1999, The International Study of Asthma and Allergies in Childhood
(ISAAC) Phase One reported the prevalence of eczema symptoms in 715,033 children from …

Background Despite unmet need, 15 years have passed since a topical therapy with a new
mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) …

Using the 2003 National Survey of Children's Health sponsored by the federal Maternal and
Child Health Bureau, we calculated prevalence estimates of eczema nationally and for each …

Importance Atopic dermatitis is associated with substantial patient and caregiver burden.
Currently available treatments for atopic dermatitis are inadequate or contraindicated for …

BACKGROUND: Recent data, primarily from Europe, suggest that children with atopic
dermatitis (AD) might be at increased risk of mental health disorders. OBJECTIVE: We aimed …

Background The adult burden of atopic dermatitis (AD) is poorly characterized. Objective We
sought to characterize AD burden in adults with moderate to severe disease from the …